Janssen’s debut at the 11th Congress of ECCO in Amsterdam!

The Janssen Immunology team is looking forward to the 11th Congress of the European Crohn’s and Colitis Organisation (ECCO), that will be taking place in Amsterdam from 16–19 March. It provides a fantastic forum for us to present our latest research into inflammatory bowel disease (IBD), particularly Crohn’s disease, to over 5,500 gastroenteorlogists and healthcare professionals from across Europe. Furthermore, it’s a great opportunity for us to find out the latest research developments from the gastroenterology community.

Janssen is proud to sponsor a symposium entitled, ‘Unmet needs and emerging therapies: a new era for Crohn’s disease management’, which will take place on Friday 18 March at 07:15–08:15 in the Plenary Hall, RAI Amsterdam. The symposium will cover how emerging therapies affect the mechanism of disease and what the most important medical needs are in the management of Crohn’s disease, including how IL-12/23 inhibitors can address the current unmet needs.

The following abstracts from Janssen were accepted:

Assessment of Serum C-reactive Protein, Fecal Lactoferrin, and Fecal Calprotectin in Patients with Crohn’s Disease: Results from the UNITI-1 and UNITI-2 Ustekinumab Induction Studies
Pharmacokinetics And Exposure-Response Relationships of Intravenously Administered Ustekinumab During Induction Treatment in Patients with Crohn’s Disease: Results from the UNITI-1 and UNITI-2 Studies
Molecular Response to Ustekinumab in Moderate-to-Severe Crohn’s Disease by Serum Protein Analysis: Results from the UNITI-1 and UNITI-2 Phase 3 Induction Studies

Janssen is committed to investing in immune and inflammatory diseases, such as Crohn’s disease, a chronic and serious condition that causes painful inflammation of the gastrointestinal tract, usually affecting the small intestine or colon.

In Europe 250,000 people are living with Crohn’s disease, with around 18,000 new cases diagnosed each year. Though anyone can be affected by Crohn’s disease at any age, it most often impacts those between the ages of 15 to 35 in both men and women.(1)

Crohn’s disease can affect people in many ways and is associated with numerous physical and psychosocial comorbidities including depression, stress, anaemia and colorectal cancer.( 2, 3, 4) It is a condition that can also significantly affect a person’s quality of life. (5) Currently, there is no cure for Crohn’s disease and so it is vital that research into new treatments continues.

Did you know…

Over 32,000 people in Europe are diagnosed with Crohn’s disease every year?(6)
Up to 20% of those affected have a close relative (parent, child or sibling) diagnosed with an IBD(7)
Around 70% of patients with Crohn’s disease will require surgery when medications and diet can no longer control symptoms or other complications arise(8)